U.S. FDA Approves Uplizna™ for the Treatment of Adult Patients with AQP4+ Neuromyelitis Optica Spectrum Disorder
Our Commitment To Patients
We believe that improving patient health begins with the science
Who We are
We are innovative, collaborative and results-driven individuals, with a shared goal to improve the lives of patients and their families
At Viela, we are working to redefine the treatment of autoimmune disease by focusing on pathways shared across various diseases. We believe this approach–which targets the underlying molecular pathogenesis of a disease–may enable us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple diseases with each product candidate. Our unique understanding of autoimmune diseases and their relationship to biological pathways, has enabled us to develop a pipeline of potential first-and best-in-class therapies for various indications, and most recently, secure our first U.S. FDA product approval in neuromyelitis optica spectrum disorder.